Grant: Collaborative Health Research Projects (NSERC partnered)
University of Toronto
$313,633.00
Screening technologies for identification of bacterial vascular dissemination inhibitors and testing of novel antibiotic-complementing therapeutic molecules
EF 2012-13
Résumé
The spread of bacteria from the initial site of infection to other parts of the body via the bloodstream (dissemination) is responsible for most of the mortality caused by bacterial infection. Infectious diseases cost the Canadian economy $3.49B/year. The Canadian biopharmaceutical industry, Industry Canada and CIHR have identified discovery and development of novel classes of antibacterials and molecules for complementing the action of existing antibiotics as a
strategic focus for Canadian innovation and development. Disrupting bacterial dissemination may provide an important antibiotic-complementing approach for limiting infectious disease progression. The proposed project will develop rapid, less costly methods for identifying and characterizing bacterial dissemination inhibitors with potential use as novel treatments for bacterial infections.
Programme
Collaborative Health Research Projects (NSERC partnered)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
270145
Name
Moriarty Tara J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Natural Sciences and Engineering Research Council of Canada (NSERC)
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Collaborative Health Research Projects - NSERC Partnered
Projecttitle
Screening technologies for identification of bacterial vascular dissemination inhibitors and testing of novel antibiotic-complementing therapeutic molecules
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$313,633
Cihrequipment2
$0
Programname2
Collaborative Health Research Projects (NSERC partnered)
Keyworddelim
Antimicrobial-Complementing Inhibitors; Bacterial Adhesion; Bacterial Extravasation; Chronic Inflammation/Arthritis; High Throughput Assay; Imaging-Based Technologies; Infection Of Cardiovascular System; Microfluidics Technologies; Microvasculature; Systemic Spread Of Pathogens
Abstract
The spread of bacteria from the initial site of infection to other parts of the body via the bloodstream (dissemination) is responsible for most of the mortality caused by bacterial infection. Infectious diseases cost the Canadian economy $3.49B/year. The Canadian biopharmaceutical industry, Industry Canada and CIHR have identified discovery and development of novel classes of antibacterials and molecules for complementing the action of existing antibiotics as a
strategic focus for Canadian innovation and development. Disrupting bacterial dissemination may provide an important antibiotic-complementing approach for limiting infectious disease progression. The proposed project will develop rapid, less costly methods for identifying and characterizing bacterial dissemination inhibitors with potential use as novel treatments for bacterial infections.
Competitiondate
201210
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Moriarty, Tara J; Simmons, Craig A
Approvedterm
3 ans 0 mois
Cihrcontribution2
Knowledge Translation Branch~ $313,633~ $0~
